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Abstract
Background
HPTN 065 (TLC-Plus) evaluated the feasibility and effectiveness of providing quarterly $70
gift card financial incentives to HIV-infected patients on antiretroviral therapy (ART) to
encourage ART adherence and viral suppression, and represents the largest study to-date
of a financial incentive intervention for HIV viral suppression. A post-trial qualitative substudy was undertaken to examine acceptability of the financial incentives among those
receiving and implementing the intervention.

Methods
Between July and October 2013, semi-structured interviews were conducted with 72
patients and 12 investigators from 14 sites; three focus groups were conducted with 12 staff
from 10 sites. Qualitative data collection elicited experiences with and attitudes about the
intervention, including philosophical viewpoints and implementation experiences. Transcripts were analyzed in NVivo 10. Memos and matrices were developed to explore themes
from different participant group perspectives.

Results
Patients, investigators, and staff found the intervention highly acceptable, primarily due to
the emotional benefits gained through giving or receiving the incentive. Feeling rewarded or
cared for was a main value perceived by patients; this was closely tied to the financial benefit
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individual participant, group, organization or
research site; (2) a commitment to securing the
data using appropriate computer technology; and
(3) a commitment to destroying or returning the
data after analyses are completed. Individuals
interested in obtaining the data set may contact the
Director of the HIV Prevention Trials Network
(hptn@fhi360.org).

for some. Other factors influencing acceptability for all included perceived effectiveness and
health-related benefits, philosophical concerns about the use of incentives for health behavior change, and implementation issues. The termination of the incentive at the end of the
study was disappointing to participants and unexpected by some, but generally accepted.
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Positive experiences with the financial incentive intervention and strategies used to facilitate
implementation led to high acceptability of the intervention, despite some reluctance in principle to the use of incentives. The findings of this analysis provide encouraging evidence in
support of the acceptability of a large-scale financial incentive intervention for HIV viral suppression in a clinical setting, and offer valuable lessons for future applications of similar
interventions.
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Conclusion

Introduction
Antiretroviral therapy (ART) is critical to reducing HIV-related morbidity and mortality [1–
5], as well as the risk of transmission to HIV-uninfected individuals [6]. Sustained adherence
to ART can achieve the levels of viral suppression necessary to prevent HIV transmission,
afford clinical benefit and avert development of resistant viral strains [7]. However, adherence
remains a key challenge to realizing the full public health potential of ART in the US and
worldwide [8–10].
The HPTN 065 (TLC-Plus) study (ClinicalTrials.gov number NCT01152918) aimed to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in
two communities: the Bronx, New York and Washington, D.C. The study was based on a
premise derived from mathematical modelling that identifying all individuals with HIV, combined with initiation of and adherence to ART, could dramatically reduce HIV incidence in a
population [11]. One component of the study tested the feasibility and effectiveness of providing financial incentives in the form of quarterly $70 gift cards for encouraging ART adherence
and sustained viral suppression.
Financial incentives have been used, with varying degrees of success, to encourage uptake
of a range of health-related behaviors [12], but remain an emerging area of research within the
realm of HIV. Few studies have tested their efficacy in encouraging ART adherence or viral
suppression [13–16], and among the latter, none have qualitatively explored their acceptability
among the recipients and implementers of financial incentives interventions. Furthermore, a
recent comprehensive systematic review of literature on the acceptability of a variety of health
promoting financial incentives concluded that there was a dearth of empirical work on their
acceptability and called for more in-depth qualitative research on this issue [17].
Between February 2011 and April 2013, 39,359 gift cards were dispensed to 9,153 patients
at sites participating in the HPTN 065 study, representing the largest study to date of a financial incentive intervention for viral suppression. A distinctive feature of the HPTN 065 study
was the use of a site-randomized design and aggregate surveillance data to determine the effectiveness of the intervention [18].
A qualitative substudy was undertaken to complement the parent study by systematically
collecting in-depth qualitative data from a subset of patients, site investigators and staff who
participated in HPTN 065, providing the opportunity for a more thorough examination of the
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diversity of experiences with and attitudes about the financial incentive intervention. In this
analysis, we examine themes related to acceptability of financial incentives among both recipients and implementers of the intervention.

Methods
Financial incentives for viral suppression in the HPTN 065 study
Nineteen HIV care facilities (10 in the Bronx, 9 in D.C.) were randomized to provide the financial incentive intervention in addition to their standard of care for adherence support, and 20
HIV care facilities (10 in Bronx, 10 in D.C.) were randomized to provide standard of care only.
HIV-infected patients on ART could qualify for a $70 gift card as often as quarterly for achieving or maintaining viral suppression, defined as HIV RNA <400 copies/mL. The amount of
the financial incentive was determined based on extensive consultation with the study community advisory group and other stakeholders during the study design phase. The quarterly interval was selected because, at the time of the study design, quarterly blood draws to monitor
CD4 cell count and viral load were recommended per guidelines for all patients except those
with long-term viral suppression [19]. In order to avoid incentivizing non-adherence that
might occur if patients had to newly achieve viral suppression, all patients at financial incentives sites were eligible to participate regardless of how long they had been virally suppressed.

Qualitative substudy
Data for the qualitative substudy were collected between July and October 2013 at a subset of
HIV care study sites that were randomized to the financial incentive intervention arm. Data
collection and analysis occurred after the intervention had ended at all sites, but before the
overall effectiveness of the incentive was assessed, so that knowledge of the effectiveness outcome would not influence participant attitudes. One-time semi-structured in-depth interviews
were conducted with patients and site investigators, and focus group discussions were conducted with site staff. Demographic information was only collected from patients. Broad
themes explored in the interviews and focus groups included: attitudes about the financial
incentive intervention; perceived influence of the intervention on behavior, clinic attendance,
and patient/provider relationships; experiences dispensing and receiving the incentives; how
the gift cards were used; motivators for viral suppression and medication adherence; patients’
understanding of the purpose of the intervention; understanding of HIV viral load and its
impact on health; and community awareness of the intervention.
Patient interviews and staff focus groups were conducted face-to-face by trained interviewers from diverse demographic backgrounds who were not affiliated with the parent study or
substudy research team. Investigator interviews were conducted over the phone by a single
member of the substudy research team trained in qualitative data collection. All interviews
were conducted in English or Spanish, audio-recorded, translated into English (if necessary),
and transcribed. Interviews lasted approximately 60 minutes, and focus groups, 90 minutes.
The substudy protocol was approved by a central IRB (Copernicus Group IRB) prior to
commencement of data collection. Additionally, all sites recruiting patients for interviews
obtained either local IRB approval (4 sites) or approval under the central IRB (10 sites). The
local IRBs reviewing this study were: Albert Einstein College of Medicine of Yeshiva University
IRB, Children’s National Health System IRB, and George Washington University and Medical
Center IRB. Written informed consent was obtained from all patients and focus group participants prior to data collection; verbal consent was obtained from investigators prior to phone
interviews. Parent/guardian consent was obtained for any participant under the age of 18,
along with informed assent of the participant.
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Substudy sample
All HPTN 065 HIV care sites randomized to the financial incentive intervention were invited
to participate in the qualitative sub-study. Those that agreed and were able to obtain IRB
approval prior to study implementation formed the subset of sites from which participants
were recruited.
For patient interviews, a non-probability, purposive, quota-based sampling strategy was
employed to ensure inclusion of a heterogeneous sample of patients who had received financial
incentives: participants were recruited within five subcategories based on HIV viral load values
(suppressed or not) prior to and during the study period, and the date of ART initiation
(before or after the intervention began) (Table 1). An initial goal of 80 patient interviews,
equally distributed between the Bronx and Washington, DC and across each of the five subcategories, was estimated to be feasible and sufficient to reach saturation. In cases in which sites
found it challenging to meet enrollment targets for some subcategories, slots were either reassigned or the “other” category was used as long as the patient met inclusion criteria, as the
intent was to ensure a diversity of participants rather than a representative sample of the parent
study.
In order to achieve a proportional distribution across subcategories and sites, participating
sites, based on patient volumes, were assigned 3 to 8 participants to recruit within each subcategory. Sites were provided with standardized talking points, but determined their own recruitment strategies. To be eligible for the qualitative substudy, patients had to currently be
enrolled in care at the site and had to have been eligible for the financial incentive intervention
for at least 15 months of the 24-month intervention.
All investigators involved in an HPTN 065 site assigned to financial incentives for at least
12 months of the 24-month financial incentive intervention were invited by email to participate in a phone interview. All but one investigator interviewed were physicians. Focus groups
included site staff members (study coordinators, nurses, social workers, research staff, and
physician assistants, but not physicians) who were directly involved in implementation of
HPTN 065 at a site assigned to financial incentives for at least 12 months of the 24-month

Table 1. Patient subcategory distributions.
Bronx
(n)

DC
(n)

TOTAL
(N)

5

8

13

Pre-defined Subcategories
ART initiated during study, VS during study ( 5 gift cards)
ART initiated during study, mixed or not VS during study ( 3 gift cards)

0

0

0

ART initiated prior to study, VS prior to study, VS during study ( 5 gift
cards)

12

14

26

ART initiated prior to study, not VS prior to study, mixed or not VS during
study ( 3 gift cards)

4

9

13

ART initiated prior to study, not VS prior to study, VS during study ( 5 gift
cards)

0

7

7

Other a
5 gift cards

7

1

8

 3 gift cards

2

3

5

TOTAL

30

42

72

a

Participant did not meet definition of pre-defined subcategories, or subcategory determination could not be
made from available data.
doi:10.1371/journal.pone.0170686.t001
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financial incentive intervention. All site staff members who met these inclusion criteria were
invited to participate in a focus group.

Qualitative data analysis
All transcripts were uploaded to NVivo qualitative analysis Software Version 10.0 (QSR International Pty Ltd.) and qualitative thematic content analysis techniques were used to analyze
the data, following a process of reading, coding, data display, and reduction [20]. To develop a
codebook, members of the substudy research team read a subset of transcripts and coded both
structural and emerging themes, reviewed coding, and refined the codebook through an iterative process until consensus and saturation were reached. The codebook was then applied to
all transcripts. Approximately 20% of patient interviews, 25% of investigator interviews, and
all focus group transcripts were double-coded, and two members of the research team manually reviewed results to ensure inter-coder reliability. Discrepancies were discussed amongst
the research team until team members agreed on interpretation; when needed, the codebook
was further clarified and transcripts recoded.
For this acceptability analysis, primary coding reports related to attitudes about the financial incentive intervention, the concept of offering financial incentives for viral suppression,
experiences in giving or receiving the financial incentives and the end of the financial incentive
program were extracted and further analyzed. Emergent sub-themes were coded and applied
to coding reports. Where applicable, Excel matrices were used to display themes and subthemes, and to identify patterns across data sources. Memos were developed to summarize
findings within each broad theme.

Results
Seventy-six patients from 14 sites completed the interview; 72 were included in this analysis
(two did not meet eligibility criteria, one never received a financial incentive, and one
appeared to be intoxicated during the interview). Additionally, 12 investigators from 14 sites
completed the interview, and three focus group discussions were conducted with 12 staff
members from 10 sites (Table 2). Patients ranged in age from 14 to 72 years (median age 48);
61% were male; 60% Black, 15% white, and 21% Hispanic (Table 3). The majority of patients
(76%) reported an annual income of less than $20,000. (Individual-level data were not collected as part of the HPTN 065 study, and the demographic data that can be ascertained from
U.S. Surveillance data for the population of patients in care at sites participating in HPTN 065
are not yet available for comparison). Patients were recruited from 4 of the 5 pre-defined subcategories; if subcategory definitions were not met, the participant was classified as “other”
(Table 1). The majority of patients (75%) had received at least five gift cards over the course of
the intervention.
Table 2. Substudy participants and sites.
Bronx

DC

TOTAL

Patient Interviews (N) / Sites (N)

30 / 7

42 / 7

72 / 14

Investigator Interviews (N) / Sites (N)

6/8a

6/6

12 / 14

Focus Groups N (participants/sites)

2 (6 / 4)

1 (6 / 6)

3 (12 / 10)

a

Two investigators from the Bronx each oversaw two research sites.

doi:10.1371/journal.pone.0170686.t002

PLOS ONE | DOI:10.1371/journal.pone.0170686 February 9, 2017

5 / 18

Acceptability of financial incentives for HIV viral suppression

Table 3. Patient characteristics.
(N = 72)

(%)

Bronx

30

42%

DC

42

58%

Location

Sex
Female

26

36%

Male

44

61%

Transgender

2

3%

Age
18

5

7%

19–25

8

11%

26–45

18

25%

>45

41

57%

Race
Black

43

60%

White

11

15%

Other

18

25%

Hispanic

15

21%

Non-Hispanic

57

79%

Heterosexual

37

51%

Homosexual

28

39%

Bisexual

7

10%

Ethnicity

Sexual Orientation

Education
Did not graduate High School/General Educational Development (HS/GED)

24

33%

HS/GED

17

24%

> HS/GED

31

43%

Personal Income in USD
<20,000

55

76%

20,000–60,000

12

17%

>60,000

4

5%

Refused to Answer

1

1%

doi:10.1371/journal.pone.0170686.t003

Nearly all patients, regardless of the number of gift cards they had received or their site,
expressed an overall positive attitude regarding the financial incentive intervention. Most
reported that their attitude had not changed over the course of the intervention, though a few
described initial skepticism and a few had neutral attitudes about the intervention. Investigators and staff felt overall very positively about the financial incentive intervention, but
expressed more mixed attitudes compared with the patients, mostly related to logistical and
other challenges experienced in implementing the intervention. Three investigators noted that
their attitudes regarding the financial incentive intervention had changed from skepticism in
the beginning to very supportive over the course of the study.
Across patients, staff, and investigators, five main factors were identified that influenced
acceptability of the financial incentive intervention: emotional benefits, financial benefits,
health-related benefits, philosophical concerns and implementation issues.
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Emotional benefits
Emotional benefits were the most commonly cited reasons why patients liked the financial
incentive intervention. Patients described feeling good, encouraged, appreciated, cared for, or
motivated when receiving the financial incentives, and that the intervention gave them something to look forward to or be excited about. Some noted that it helped counteract the negative
feelings normally associated with thinking about their HIV infection.
“And then incentives make you feel good. I mean it just makes you like ‘Okay, yay!; I got something to look forward to when I go back as long as I’m doing my medicines and eating right
and stuff like that. . . The happy face and the handshake is good but, yeah, a [gift card] makes
it even better.”
(Patient, non-Hispanic black female, 48 years old)
“Well, what I really liked about it is knowing that someone is there thinking of us and someone
is there reaching out to us. . .. In a way you know you're already ill and stuff like that. . .. Most
of all, it makes you feel like someone cares.”
(Patient, non-Hispanic black male, 50 years old)
Investigators and staff described overall positive opinions of the financial incentive intervention, largely attributed to emotional benefits, such as positive interactions with patients
during the gift card exchange, improved morale among clinic staff and providers, and feeling
good about being able to provide positive reinforcement or do something to help someone in
need.
“What I liked about the study was that, when you have patients that don’t have any money to
buy food or toilet paper and they would come to you with a smile on their face because they
have $70 to spend on something they were not going to be able to buy, something that they
needed–it’s not even things that they just wanted, it’s needed–[handing out gift cards] made
me feel good.”
(Staff member)
“I think [providers] saw an excitement among their patients that they loved to see. Their
patients were so happy. Whereas sometimes, a patient has to force him or herself to come in for
a visit, but here they were happy to come in for a visit. They were happy to be seen, to get their
blood drawn. They were reminding the doctor it was time to get their blood drawn.”
(Investigator)
Some investigators indicated that they appreciated these positive benefits so much that they
would gladly implement a financial incentive intervention again in the future, whether or not
financial incentives could improve viral suppression.
“My primary reason [for wanting to implement the financial incentive intervention in the
future] is to provide the system of positive reinforcement . . . even if it doesn’t fully work. I
don’t know the end results of the study. . . . I think it improved the dynamic of my staff in the
clinic. I think we felt empowered to do something for our [patients], beyond what we do
already. We do know how many of them struggle financially. We heard many positive comments.”
(Investigator)
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A couple of investigators indicated that they had been opposed to the idea of offering financial incentives for viral suppression at the start of the study, but were in favor by the end
because it had been such a positive experience.
“My patients thought it was an absolutely fabulous idea. . . . And so, frankly, over the course of
the study, my attitude changed. And I became as enthusiastic as my patients were because for
them this was really something that was quite exciting and they felt that they were really participating in something that was really very good.”
(Investigator)
Some staff, however, noted a negative emotional consequence in that they felt the financial
incentives created a sense of entitlement in a minority of patients who became aggressive or
demanding about receiving their incentive. Most of the staff who described these negative
experiences still seemed to have overall positive opinions about the financial incentive intervention. However, for a few staff, these experiences seemed to be central and negatively
affected acceptability for them.
“[I] definitely had a positive experience. [The financial incentive intervention] lets you get connected with the patients a little more. They definitely appreciated it. You got to know certain
patients on a different level. At the same time, there were those patients . . . who felt entitled to
get the gift card; very rude about [it] when they came to get it. Who, you know, I don’t think
they cared about the viral suppression, they just wanted the money.”
(Staff member)
“I really hated the entitlement and so many people getting mad at me, cursing at me because
this is their gift card. People acted like this is their paycheck, like they worked for hours to get a
gift card here. Like, ‘I deserve it! I took my medication.’ And sometimes I had to step back and
say, ‘This is for your health, you know that, right? It’s not just about the money.”
(Staff member)

Financial benefits
Many patients described appreciating the financial aspects of the incentive. Most of these
patients indicated that the financial incentives helped them meet their fiscal needs, and they
described using the funds for necessities such as groceries, school supplies, bills, transportation, co-pays, or household and personal essentials. A number of patients also enjoyed the
extra resources as a special treat, and described buying non-essential or other items either for
themselves or for others as a gift, or giving the gift card itself as a gift.
“What I like about it, it was very helpful. Very helpful to me and it was very surprising like I
said. . . . It helped me pay for my medicine. Then I got a few little personal things that females
should have. . . . It helped me buy some groceries, you know, buy some eggs and stuff like that
. . . Like I said, it was very helpful.”
(Patient, non-Hispanic black female, 50 years old)
“The program helped me because even though I have HIV it gave me something to look forward to every three months, buy me an outfit and make me feel good about myself.”
(Patient, non-Hispanic black female, 55 years old)
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Nearly all patients, when asked, reported that they were happy with the $70 amount of the
financial incentive. Although some also said they would have been happier with a higher
amount, only three patients expressed that the incentive was not high enough, while two
thought it was too high.
“I think it's a good amount. I think, at that level, it's a very positive incentive. I think if it was
less, if it was like $25 or so, people who may not generally keep their appointments probably
wouldn't do it for $25, unless they were motivated in terms of their health. But I thought $70
was very generous.”
(Patient, non-Hispanic black male, 66 years old)
“Well to be honest, we could use more, definitely use more, but $70 wasn't bad, it helped.”
(Patient, Hispanic mixed race female, 57 years old)

Health-related benefits
A number of patients, investigators, and staff discussed the perceived effectiveness of the financial incentives in incentivizing desirable health-related behaviors or outcomes as a reason why
they liked the intervention. Many of these patients did not feel that they themselves needed the
financial incentive to be motivated to take their medication, but speculated that it was useful
for others who have trouble with adherence.
“Like, everybody's different. For me, you don't actually have to pay me, because, like I said, I
see my doctor on a regular basis anyway. My health is very important to me. But for people
[that aren’t adherent] to taking medication and seeing their doctors on a regular [basis], I
think that program worked for them, because it got them in a routine of going and seeing their
doctors regularly.”
(Patient, non-Hispanic black female, 51 years old)
Furthermore, many of the health benefits described commonly by patients, investigators and
staff were not limited to viral suppression and ART adherence, but more broadly included the
perception that the card encouraged people to get in the routine of seeing their doctor and to be
more proactive in their own healthcare. Some investigators and staff also felt that the financial
incentive provided opportunities to encourage other, necessary, healthcare evaluations.
“It was cool. I mean, it's a good incentive thing to, you know, stay with your drugs and keep
your viral load undetectable and all that stuff. . .it's something I think most people strive to do
anyway once you get started, but it's definitely an extra incentive to, you know, get you into
the doctor as well as just keeping, you know, taking your meds and everything.”
(Patient, non-Hispanic white male, 55 years old)
“We [also] got some of them to do some of their other things: their PAP smears and their
EKGs and things like that. So I think, you know, I think it’s a good thing. I would want to do
it again.”
(Investigator)
“None of us knew how much better our patients would do with it . . . we certainly knew that
our patients were adhering to care much better. . .They were certainly much more interested in
their results and getting their results back. . .And for a percentage of patients, . . . they were
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certainly taking their meds better, at least some percentage. So I think, you know, the providers
actually really liked it.”
(Investigator)

Philosophical concerns
When asked specifically about the concept of paying someone to achieve viral suppression,
some patients had mixed reactions. While they acknowledged potential and real benefits to
financial incentives, they also expressed concern that patients should be self-motivated to do
what is in their own best interest. In this way, a number of patients described a philosophical
conflict with the concept of offering financial incentives for viral suppression.
“People should want to just be healthy. . . you shouldn't want to get paid to take your medication.”
(Patient, non-Hispanic black female, 22 years old)
“I mean overall, a gift card shouldn't be . . . what's the word I'm looking for? A bribe, to do the
right thing for your own health, but maybe some people don't have any money, so I guess it's
. . . it's a good thing.”
(Patient, Hispanic mixed race transgender, 23 years old)
Several investigators and staff also described this philosophical conflict whereby they
reported enjoying the intervention and thought it had some benefits, but similarly felt that
patients should be self-motivated to stay healthy without the need for financial incentives.
“I think it was helpful because even if people take their medicine every day it’s still a positive
thing to get the money. . .Some type of reward even though, you know, you shouldn’t get a
reward for doing what you’re supposed to do.”
(Staff member)
Among those who expressed concern, some also described a philosophical conflict with the
study design which required giving incentives to patients who may already be suppressed.
These individuals felt that, for adherent patients, the financial incentive becomes a reward
rather than an incentive, or that because resources for financial incentives may be difficult to
sustain they should, therefore, be targeted to patients struggling to achieve and/or maintain
their medication adherence.
“I think part of the problem was that in offering incentives to everybody, it wasn’t really incentives, it was [a] reward for many patients who [were] already suppressed.”
(Investigator)
Only a handful of patients completely disagreed with the concept of offering financial
incentives for viral suppression, thinking that it was a waste of money or that it might
create a divide between those who are able to achieve viral suppression versus those who are
not.
No investigators or staff expressed complete opposition to the concept, though one investigator recounted initial strong resistance among providers at his clinic that quickly dissipated
once the intervention started and benefits were observed.
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Implementation issues
The main challenges to acceptability for investigators and staff were related to implementation
issues; the primary one being the requirement for quarterly viral load tests to qualify for financial incentives in the study. Although this schedule was intended to streamline and simplify
study procedures, it did not always align with clinical care at some sites, particularly for stable
patients with long-term virologic suppression who did not require such frequent monitoring
[19]. This may have resulted in more crowded clinics as more patients kept their appointments
or visited the clinic more frequently in order to get viral load measurements to qualify for
financial incentive. Although some, particularly investigators, saw this increased engagement
in care as a benefit, some also acknowledged that it increased demands on staff time and space,
and sometimes interfered with clinic flow.
“We experienced significantly higher patient volume because patients were showing up for
their visits and also were wanting to be rescheduled every three months, whereas otherwise
they might have begged and pleaded for four month visits or six month visits or even not have
scheduled right away when they left the clinic at a previous appointment. So it was a challenge
for us to deal with a steadier volume.”
(Investigator)
Some staff and investigators reported that they, or the providers they worked with, felt obligated to schedule visits or lab work around the requirements for gift card eligibility rather than
clinic availability, space, or patient needs, and some resented this.
“The study calls for its own needs in terms of CD4 and viral load draws. And meanwhile clinical care has sometimes different demands. . . .meaning that providers might not always see the
need to send the CD4 and viral load on a given date. But the patient feels that if they don’t
have CD4 and viral load done on those dates, they don’t get their incentives card. So there’s
some times it led to conflicts between the study and the clinical care.”
(Investigator)
Other logistical challenges, though generally described as minor, may have also affected the
acceptability of the financial incentive intervention for investigators and staff. Implementation
required disbursing gift cards to patients, monitoring and tracking gift card inventory, ensuring safe storage of gift cards, and tracking gift card disbursement with paper forms and an
electronic database. Study procedures were designed to be minimal and allow for flexible integration into workflow, but some investigators and staff noted an increased administrative burden, particularly in large clinics with a high volume of patients.
“I think that there were issues around the gift cards and making sure we kept them straight
and making sure nothing got stolen. That was a big stress among the providers, and that we
kept track of them properly. . .the operational issues were not without attention and some
degree of vigilance. . .it was an extra layer of activity on an already burdened system, with adequate staff to do it, but still you had to implement and coordinate that, and that was a learning
stress.”
(Investigator)
It was noted that logistical challenges were reported to have largely occurred during the initial phases of the study. Sites were given flexibility to develop their own processes for gift card
distribution, and many described a learning curve as procedures, clinic flow, and gift card and
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patient tracking were improved, and attributed smooth implementation to well-trained and
dedicated study staff.
“By the end of it, it was just going off seamlessly”
(Investigator).
“I think that we were very fortunate to have the young ladies that we had work on our study
here. And they did a great job. And I think they learned very much how to work with the flow
of the clinic, work with the providers, and work with the patients so that it really became much
smoother over time.”
(Investigator)
Patients, on the other hand, largely reported no negative effect on their clinic visit experience or implementation of financial incentive intervention. Only a few noted difficulties such
as longer wait times or record keeping errors related to the financial incentive intervention.
Overall, implementation issues did not emerge as a theme related to acceptability of financial
incentives among patients.

Conclusion of the financial incentive intervention
The financial incentive intervention took place for a two-year duration at all sites. Patients for
the most part felt neutral or slightly disappointed that they were no longer receiving the financial incentives, and some acknowledged that they had always expected the intervention to end.
While disappointed to no longer be receiving gift cards, these patients understood the often
provisional nature of interventions and financial resources.
“I was a little disappointed. It was a nice benefit, you know. It was . . . but I understand.
Money runs out and things are done.”
(Patient, non-Hispanic white male, 48 years old)
Only a few patients described being distraught about the end of the intervention, indicating
that they counted on it financially, or suggesting that they were only adherent because of the
gift cards. One participant jokingly said
“It’s like I broke up with my best friend. . . I have a heartache.”
(Patient, non-Hispanic black female, 52 years old)
When describing how they were informed about the end of the financial incentive intervention, several patients used language such as “they dropped” (Patient, non-Hispanic black male,
58 years old), or “they just kind of discontinued” (Patient, non-Hispanic, black male, 34 years
old), the intervention, indicating that there may not have been clear understanding among all
patients from the start that it was only a two-year intervention as part of a research study.
A handful of patients also noted that the way they were informed about the intervention
ending was not ideal.
“When I came back for my results, I thought I was gonna get [a gift card]; that’s when they
told me, ‘we don’t give ‘em [out] no more’. There should have been a sign, to tell me.”
(Patient, Hispanic mixed race male, 57 years old)
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Despite feelings of disappointment to varying degrees, as well as different experiences in how
the end of the intervention was communicated, most patients indicated that the lack of financial
incentives beyond the study would not change their reasons for taking their medication.
“I felt sad, because I got used to having [the financial incentive]. But still, I was still continuing
doing my meds anyway, you know? So it wasn't that I'm taking it for that, for the gift cards,
you know. So, it was just an incentive that ended.”
(Patient, Hispanic black male, 51 years old)
Investigators likewise perceived this disappointed-but-accepting sentiment among patients,
noting an “it was good while it lasted” (Investigator) mentality.
“Patients are adjusting to the lack of incentives very, very well. And I haven't seen anybody
who's stopped taking their meds now that they're off incentives.”
(Investigator)
Most investigators did not expect or notice any major impact, positive or negative, on their
clinic or patients due to the end of the intervention, though they acknowledged that it may
take more time to see the full effect, if any.
“I don't think I've seen an impact on our staff. I think they're disappointed they can't offer [the
incentive] anymore, but, you know, they've got so much going on that. . .they've moved on. I
think the patients are disappointed, like having a rich uncle come through and then he
leaves. . .. But . . . we haven't seen this change long enough to know what impact that'll have.”
(Investigator)
Staff expressed more concern about the end of the program than investigators. Concerns
were primarily related to anticipated or observed decreases in visit attendance, though some
also speculated about potential detrimental effects on adherence or the financial stability of
patients who had become dependent on incentives.
“[The end of the financial incentive intervention will have a] major impact on our clinic.
Major. . .and it saddens us that a lot of [patients] were taking [medication] or were encouraged
to take it based on receiving the gift card. It’s just sad. But we have several that are actually
adherent to their medication and coming, but the visits are not as regular as they were.”
(Staff member)

Discussion
Few studies have qualitatively explored the acceptability of financial incentives when used for
health-related behavior change (particularly related to HIV), and among those that have, the
populations studied have mostly been the general public, potential recipients, and/or potential
implementers of a hypothetical financial incentive [12]. This study is unique in that it explored
acceptability of financial incentives among actual recipients (patients) and implementers
(investigators and staff) of a large-scale multi-site study about the feasibility and effectiveness
of financial incentives for viral suppression among HIV-infected patients on ART. In addition,
the strategic timing of the qualitative data collection and analysis—before study results on the
effectiveness of the intervention were available—enabled the sharing of impressions, beliefs
and attitudes based primarily on experiences with the financial incentive intervention, without
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the influence of the study outcome and any subsequent related discourse. The findings of this
substudy reveal important insights into how a financial incentive intervention for health
behavior change may be best implemented in a clinical setting. Regardless of how effective any
biomedical or behavioral interventions are in the context of a clinical trial, or how great the
need for them may be, their success relies in great part on user acceptance, uptake, and adherence. Qualitative studies like this one, in complement to clinical trials, are important tools for
understanding the real-world contexts in which tested interventions are implemented and the
factors necessary to ensure that they are acceptable to those they are intended to help.
Results from this study suggest that patients, investigators, and staff found the financial
incentive intervention highly acceptable. By far the strongest facilitator of acceptability
reported by both recipients and implementers was that participating in the intervention made
them feel good: nearly all of those interviewed found the intervention to be a beneficial and
positive experience. For many patients, this was closely tied to the receipt of a financial benefit
and the additional resources it afforded, although just the positive feeling of being rewarded or
cared for was a principle value for some.
In a small pilot study of financial incentives for viral suppression, Farber et al. likewise
found the intervention to be acceptable to both recipients and implementers [21], but the
strong emotional element identified in our analysis is novel and has not been previously
reported [17, 22]. The significance of emotional benefits to implementers was unexpected and
is noteworthy as emotional benefits seemed to be a key factor in mitigating implementation
and other challenges that could potentially hinder acceptability. However, more research is
warranted on the contribution of these emotional benefits to the mechanism of action of financial incentives in changing behavior. The shared emotional benefit also provides a new dimension to the concept of ‘fair exchange’ which has been identified by others as a key determinant
in the acceptability of financial incentives. Previously this concept was conceived of as an
exchange of benefits derived from the incentivized behavior, the incentive itself, and health
improvement, without an emotional component on either side of the equation [17].
The findings from this study may allay concerns raised by some that offering financial
incentives may compromise the provider-patient relationship that is founded on trust [23, 24].
In fact, in this study, the financial incentive intervention generally seemed to foster a stronger
and more positive relationship. However, in rare circumstances, interactions with aggressive
or “entitled” patients created negative impressions for staff members. These incidents, though
not frequently noted, nonetheless indicate that financial incentives do have the potential for a
negative effect on provider/patient interactions. If not undertaken in an environment of
mutual respect and open communication, financial incentives may potentially be detrimental
to patient-provider relationships. Setting clear expectations may help to reduce the potential
for these negative interactions, and having a plan in place to help staff prevent or manage incidents may offset any damaging consequences.
The findings of this study also revealed complex conflicting feelings regarding offering
financial incentives for health behaviors, highlighting a ‘philosophical conflict’ whereby the
financial incentive intervention was acceptable and even gratifying, but associated with
reported concerns, even among recipients themselves, that one should not have to ‘pay people
to do what is good for them.’ This sentiment is not unique and has been cited in the literature,
reflecting a common perception of wider societal beliefs with regard to the use of health-promoting incentives [17, 22, 25, 26]. Our findings suggest that some individuals who might be
theoretically opposed may change their thinking after a tangible and positive experience.
We found that the specific incentive that was offered in HPTN 065 –a $70 gift card–was
highly acceptable to the participants in this study. However, the quarterly disbursement schedule, while desirable for patients, proved to be at times disruptive for providers as it was more
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frequent than expected or needed for many patients. These findings support previous studies
which have found that financial incentive acceptability may depend on the type, format, size
and scheduling of the incentives [17]. Further research is needed to investigate the optimal frequency of financial incentives for effectiveness, feasibility, and acceptability.
Sustainability is a common concern in the context of financial incentive interventions, with
some fears that such rewards may create a beneficial effect that does not persist due to dependence on a financial resource that may only be temporary [23, 25, 27]. While these concerns
were echoed by some investigators and staff interviewed, for patients, the discontinuation of
the financial incentives at the end of the study was disappointing but generally accepted. In
some cases, the planned discontinuation could have been communicated more effectively.
While there was largely no indication that the end of this intervention would have detrimental
effects on medication adherence behaviors, it should be noted that, at the time of this publication, it is not known whether or not patients who received financial incentives were able to
maintain viral suppression after the end of the intervention.
Previous studies, mostly conducted amongst the general population and which involved
hypothetical financial incentives, have found that the most consistent and strongest factor
influencing their acceptability was the demonstrated effectiveness and cost-effectiveness of the
incentive [17, 22, 28]. Likewise, we found that the perceived or observed effectiveness of the
financial incentives in this study seemed to be a factor for some; however, our findings differed
from previous studies in that we noted other, perhaps even stronger factors influencing acceptability by the participants, while cost-effectiveness specifically was not indicated as a factor.
Our findings suggest that high acceptability may be possible in the context of unknown effectiveness of financial incentives.
This study had several limitations. Participants were drawn from a convenience sample
and, thus, are not representative of all those participating in the HPTN 065 study or the wider
population of HIV-infected individuals. The intent was to examine a diversity of experiences,
however, it is possible that those who did not have positive experiences with the intervention
may have been less likely to agree to participate in the study. This may be supported by the fact
that the study sample was comprised mostly of patients who had received five or more gift
cards. Further, patients may have been overly motivated to receive one final financial incentive
in the form of compensation for their participation in the interviews, and thus may have been
more likely to report positive opinions. It also should be noted that the majority of the substudy sample was low income and thus may have been more beneficially affected by the incentives than a higher-income population. Additionally, the findings may not be applicable to
settings outside of the United States or even in different domestic contexts. Investigators were
interviewed for the substudy by a member of the HPTN 065 protocol team with whom they
may have had a professional relationship during the course of the study, which presents the
possibility of social desirability bias. However, our review of interview transcripts provides
no evidence for this given the forthright and sometimes critical nature of some investigator
reflections.

Conclusion
HPTN 065 represents the largest study to-date of the use of financial incentives among HIVinfected patients receiving ART to maintain viral suppression. The success and long-term sustainability of financial incentive interventions are dependent on their acceptability by both
recipients of the incentive as well as by those implementing the intervention. Positive experiences with the financial incentive intervention in the HPTN 065 study and strategies used to
overcome implementation challenges facilitated high acceptability of the intervention, despite
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some resistance in principle to the use of financial incentives to influence health behaviors.
The findings of this analysis provide encouraging evidence for the acceptability of a large-scale
financial incentive intervention for viral suppression in a clinical setting, and offer valuable lessons for the future use of financial incentives.

Acknowledgments
We would like to thank the patients, investigators, staff, and study sites who participated in the
qualitative substudy as well as the HPTN 065 parent study. We would also like to acknowledge
the contributions of the entire HPTN 065 protocol team, under the leadership of Drs. Wafaa
M. El-Sadr and Bernard M. Branson, whose members can be viewed at https://hptn.org/
research/studies/77.

Author contributions
Conceptualization: EG TG EET VS WES BMB.
Data curation: EG TG.
Formal analysis: EG TG AP EET JS JT VS.
Funding acquisition: WES BMB TG EG.
Investigation: JL NR.
Methodology: EG TG EET.
Project administration: EG TG VS.
Resources: JL NR.
Supervision: EG TG EET WES BMB.
Validation: EG TG AP JS JT VS.
Visualization: EG.
Writing – original draft: EG.
Writing – review & editing: EG AP JS VS EET JT WES BMB NR TG.

References
1.

Lewden C, Chêne G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4
cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach aame mortality rates as the general population. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2007;
46(1):72–7. doi: 10.1097/QAI.0b013e318134257a PMID: 17621240

2.

Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern
highly active antiretroviral therapy regimens and adherence on mortality over time. JAIDS Journal of
Acquired Immune Deficiency Syndromes. 2009; 50(5):529–36. doi: 10.1097/QAI.0b013e31819675e9
PMID: 19223785

3.

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity
and mortality among patients with advanced human immunodeficiency virus infection. New England
Journal of Medicine. 1998; 338(13):853–60. doi: 10.1056/NEJM199803263381301 PMID: 9516219

4.

Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in
the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general
population. AIDS. 2013; 27(6):973–9. doi: 10.1097/QAD.0b013e32835cae9c PMID: 23698063

5.

Sterne JAC, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of
potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. The Lancet. 366
(9483):378–84.

PLOS ONE | DOI:10.1371/journal.pone.0170686 February 9, 2017

16 / 18

Acceptability of financial incentives for HIV viral suppression

6.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of
HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011; 365(6):493–
505. doi: 10.1056/NEJMoa1105243 PMID: 21767103

7.

Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 2008; 61(4):769–73. doi: 10.1093/jac/dkn020 PMID: 18256112

8.

Cooke CE, Lee HY, Xing S. Adherence to antiretroviral therapy in managed care members in the United
States: a retrospective claims analysis. Journal of managed care pharmacy: JMCP. 2014; 20(1):86–92.
doi: 10.18553/jmcp.2014.20.1.86 PMID: 24372462

9.

Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy
in sub-Saharan Africa and North America: a meta-analysis. Jama. 2006; 296(6):679–90. doi: 10.1001/
jama.296.6.679 PMID: 16896111

10.

Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S, et al. HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010
AIDS treatment for life international survey. Journal of the International Association of Physicians in
AIDS Care (JIAPAC). 2012; 11:128–33.

11.

Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The
Lancet. 2009; 373(9657):48–57.

12.

Giles EL, Robalino S, McColl E, Sniehotta FF, Adams J. The effectiveness of financial incentives for
health behaviour change: systematic review and meta-analysis. PloS One. 2014; 9(3):e90347. doi: 10.
1371/journal.pone.0090347 PMID: 24618584

13.

Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C. Efficacy of an individualized adherence
support program with contingent reinforcement among nonadherent HIV-positive patients results from
a randomized trial. Journal of the International Association of Physicians in AIDS Care (JIAPAC). 2006;
5(4):143–50.

14.

Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, et al. Voucher
incentives improve linkage to and retention in care among HIV-infected drugs users in Chennai, India.
Clinical Infectious Diseases. 2014:ciu324.

15.

Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, Cramer J, et al. Improved adherence with
contingency management. AIDS patient care and STDs. 2007; 21(1):30–40. doi: 10.1089/apc.2006.
0028 PMID: 17263651

16.

Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, et al. Voucher reinforcement
improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug and alcohol dependence. 2007; 88(1):54–63. doi: 10.1016/j.drugalcdep.2006.09.019 PMID: 17056206

17.

Giles EL, Robalino S, Sniehotta FF, Adams J, McColl E. Acceptability of financial incentives for encouraging uptake of healthy behaviours: a critical review using systematic methods. Preventive medicine.
2015; 73:145–58. doi: 10.1016/j.ypmed.2014.12.029 PMID: 25600881

18.

Donnell DJ, Hall HI, Gamble T, Beauchamp G, Griffin AB, Torian LV, et al. Suppl 1: Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study:
HPTN 065. The open AIDS journal. 2012; 6:122. doi: 10.2174/1874613601206010122 PMID:
23049660

19.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. Laboratory Testing: Department of Health and Human
Services; 2015. p. C-6.

20.

Tolley EE, Ulin PR, Mack N, Robinson ET, Succop S. Qualitative methods in public health: a field guide
for applied research. 2nd ed: John Wiley & Sons; 2016.

21.

Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, et al. A study of financial incentives to reduce
plasma HIV RNA among patients in care. AIDS and Behavior. 2013; 17(7):2293–300. doi: 10.1007/
s10461-013-0416-1 PMID: 23404097

22.

Giles EL, Sniehotta FF, McColl E, Adams J. Acceptability of financial incentives and penalties for
encouraging uptake of healthy behaviours: focus groups. BMC public health. 2015; 15(1):58.

23.

Marteau TM, Ashcroft RE, Oliver A. Using financial incentives to achieve healthy behaviour. Bmj. 2009;
338.

24.

Oliver A, Brown LD. A consideration of user financial incentives to address health inequalities. Journal
of Health Politics, Policy and Law. 2012; 37(2):201–26. doi: 10.1215/03616878-1538602 PMID:
22147947

25.

Petry NM. Contingency management treatments: controversies and challenges. Addiction. 2010; 105
(9):1507–9. doi: 10.1111/j.1360-0443.2009.02879.x PMID: 20707772

PLOS ONE | DOI:10.1371/journal.pone.0170686 February 9, 2017

17 / 18

Acceptability of financial incentives for HIV viral suppression

26.

Promberger M, Brown RC, Ashcroft RE, Marteau TM. Acceptability of financial incentives to improve
health outcomes in UK and US samples. Journal of medical ethics. 2011; 37(11):682–7. doi: 10.1136/
jme.2010.039347 PMID: 21670321

27.

Gneezy U, Meier S, Rey-Biel P. When and why incentives (don’t) work to modify behavior. The Journal
of Economic Perspectives. 2011:191–209.

28.

Promberger M, Dolan P, Marteau TM. “Pay them if it works”: Discrete choice experiments on the
acceptability of financial incentives to change health related behaviour. Social science & medicine.
2012; 75(12):2509–14.

PLOS ONE | DOI:10.1371/journal.pone.0170686 February 9, 2017

18 / 18

